- Home
- RUM vs PTGX Comparison
RUM vs PTGX Comparison
Compare RUM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUM | PTGX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 5.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | RUM | PTGX |
|---|---|---|
| Price | $6.54 | $86.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $15.00 | ★ $90.56 |
| AVG Volume (30 Days) | ★ 2.4M | 984.0K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | $103,782,153.00 | ★ $209,217,000.00 |
| Revenue This Year | $7.04 | N/A |
| Revenue Next Year | $171.73 | $288.98 |
| P/E Ratio | ★ N/A | $122.09 |
| Revenue Growth | ★ 21.17 | N/A |
| 52 Week Low | $5.11 | $33.70 |
| 52 Week High | $15.10 | $96.54 |
Technical Indicators
Market Signals| Indicator | RUM | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 49.52 |
| Support Level | $6.49 | $84.11 |
| Resistance Level | $7.18 | $89.61 |
| Average True Range (ATR) | 0.35 | 3.06 |
| MACD | -0.05 | -0.70 |
| Stochastic Oscillator | 17.74 | 25.26 |
Price Performance
Historical ComparisonAbout RUM Rumble Inc.
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.